{"product_id":"advacan-0-25-tablets","title":"Advacan-0.25 Tablets","description":"\u003ch2 data-path-to-node=\"5\"\u003eIntroduction to Advacan-0.25 Tablets\u003c\/h2\u003e\n\u003cp data-path-to-node=\"6\"\u003eAdvacan-0.25 Tablet contains the active substance Everolimus. It belongs to a group of medicines known as immunosuppressants, specifically acting as a selective mTOR (mammalian target of rapamycin) inhibitor. In its lower strengths (such as 0.25mg), it is primarily indicated for the prophylaxis of organ rejection in adult patients receiving an allogeneic kidney or liver transplant. It is typically used in immediate combination with a cyclosporine microemulsion and corticosteroids to provide a multi-targeted immunosuppressive drug regimen.\u003c\/p\u003e\n\u003cp data-path-to-node=\"7\"\u003eEverolimus works by binding to an intracellular protein (FKBP-12), and this complex subsequently blocks the activation of the mTOR kinase. Because mTOR is a central regulator of cell translation, growth, and survival, inhibiting it prevents T-lymphocytes from multiplying and responding to interleukin-2 (IL-2) signals. By shutting down this critical arm of the immune system, Advacan-0.25 prevents your body's immune cells from recognizing and attacking the newly transplanted organ, ensuring long-term graft survival.\u003c\/p\u003e\n\u003cp data-path-to-node=\"8\"\u003eAdvacan-0.25 Tablets must be used under the strict, regular supervision of a transplant specialist, nephrologist, or hepatologist. The dosage must be carefully monitored, and routine blood tests are mandatory to measure the exact trough levels of the drug in your system to prevent under-dosing (rejection) or over-dosing (toxicity).\u003c\/p\u003e\n\u003cp data-path-to-node=\"9\"\u003eBefore starting treatment, inform your healthcare professional if you have a history of high cholesterol or triglycerides, liver impairment, severe respiratory conditions, diabetes, or an active infection. Seek immediate emergency medical care if you develop unexpected respiratory symptoms (such as a sudden cough or breathing difficulties), a high fever, signs of a localized infection, or delayed healing of your surgical wound site.\u003c\/p\u003e\n\u003ch2 data-path-to-node=\"10\"\u003eUses of Advacan-0.25 Tablets\u003c\/h2\u003e\n\u003cp data-path-to-node=\"11\"\u003eUses of Advacan-0.25 Tablets:\u003c\/p\u003e\n\u003cul data-path-to-node=\"12\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,0,0\"\u003ePrevention of organ rejection in adult patients undergoing an allogeneic kidney transplant.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,1,0\"\u003ePrevention of organ rejection in adult patients undergoing an allogeneic liver transplant.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,2,0\"\u003ePreservation of long-term graft function when used in combination therapy following organ transplantation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"13\"\u003eTherapeutic Effects of Advacan-0.25 Tablets\u003c\/h2\u003e\n\u003cp data-path-to-node=\"14\"\u003eAdvacan-0.25 Tablets exert their therapeutic effect by putting a strategic brake on your body's immune responses. By directly blocking the mTOR cellular signaling pathway, the drug prevents lymphocyte proliferation from passing from the G1 phase into the S phase of cell division. This selective suppression lowers the counts and activities of specific white blood cells that would otherwise target the tissue antigens of the transplanted organ. Consequently, it establishes immune tolerance, minimizes the risk of sudden acute rejection episodes, and preserves the functional integrity of the graft.\u003c\/p\u003e\n\u003ch2 data-path-to-node=\"15\"\u003eInteraction of Advacan-0.25 Tablets with other drugs\u003c\/h2\u003e\n\u003cp data-path-to-node=\"16\"\u003eIt is important to inform your healthcare professional about all the medications you are taking, including prescription drugs, over-the-counter medications, nutritional supplements, and herbal products. Some medications may interact with Advacan-0.25 Tablets, potentially affecting their effectiveness or causing serious side effects. Notable interactions include:\u003c\/p\u003e\n\u003cul data-path-to-node=\"17\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,0,0\"\u003e\u003cb data-path-to-node=\"17,0,0\" data-index-in-node=\"0\"\u003eStrong CYP3A4 and P-gp Inhibitors (Ketoconazole, Itraconazole, Ritonavir, Clarithromycin):\u003c\/b\u003e These can dramatically increase the levels of Everolimus in your blood, increasing the risk of dangerous side effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,1,0\"\u003e\u003cb data-path-to-node=\"17,1,0\" data-index-in-node=\"0\"\u003eStrong CYP3A4 and P-gp Inducers (Rifampicin, Phenytoin, Carbamazepine, St. John's Wort):\u003c\/b\u003e These can heavily lower Everolimus levels, potentially causing the medicine to fail and increasing the risk of organ rejection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,2,0\"\u003e\u003cb data-path-to-node=\"17,2,0\" data-index-in-node=\"0\"\u003eCyclosporine:\u003c\/b\u003e Co-administration increases the absorption of Everolimus. Your doctor will carefully adjust the doses of both drugs when used together.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,3,0\"\u003e\u003cb data-path-to-node=\"17,3,0\" data-index-in-node=\"0\"\u003eLive Vaccines:\u003c\/b\u003e You must avoid all live vaccines during treatment, as the drug suppresses your immune defenses and elevates the risk of vaccine-derived infections.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"18\"\u003eMore Information about Advacan-0.25 Tablets\u003c\/h2\u003e\n\u003cul data-path-to-node=\"19\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"19,0,0\"\u003eKeep out of reach of children and pets.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"19,1,0\"\u003eStore in a dry place at a temperature not exceeding 25°C.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"19,2,0\"\u003eKeep the tablets stored in their original blister pack inside the outer carton box to protect the medication from light and moisture.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"20\"\u003eHow to consume Advacan-0.25 Tablets\u003c\/h2\u003e\n\u003cp data-path-to-node=\"21\"\u003eAdvacan-0.25 Tablets are oral medications meant to be swallowed whole with a glass of water. Do not crush, chew, or split the tablets. Take your dose exactly as directed by your transplant team. You must take this medication consistently \u003cb data-path-to-node=\"21\" data-index-in-node=\"238\"\u003eeither always with food or always on an empty stomach\u003c\/b\u003e to keep blood levels stable. Never switch your routine from day to day. Avoid consuming grapefruit, grapefruit juice, or Seville oranges while taking Advacan-0.25, as they interfere with the enzymes that break down the drug, leading to toxic levels in your body.\u003c\/p\u003e\n\u003ch2 data-path-to-node=\"22\"\u003eSafety Advice for Advacan-0.25 Tablets\u003c\/h2\u003e\n\u003ch3 data-path-to-node=\"23\"\u003eBreast Feeding\u003c\/h3\u003e\n\u003cp data-path-to-node=\"24\"\u003e\u003cb data-path-to-node=\"24\" data-index-in-node=\"0\"\u003eUnsafe\u003c\/b\u003e It is unknown if Everolimus passes into human breast milk. However, due to the high risk of serious cellular side effects and immunosuppression in the infant, breastfeeding is contraindicated during treatment and for 2 weeks after the final dose.\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"25\"\u003eAlcohol\u003c\/h3\u003e\n\u003cp data-path-to-node=\"26\"\u003e\u003cb data-path-to-node=\"26\" data-index-in-node=\"0\"\u003eCaution\u003c\/b\u003e Minimize or avoid alcohol consumption while taking Advacan-0.25. Alcohol can complicate liver metabolism panels and aggravate secondary side effects like headaches or dizziness.\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"27\"\u003eLiver\u003c\/h3\u003e\n\u003cp data-path-to-node=\"28\"\u003e\u003cb data-path-to-node=\"28\" data-index-in-node=\"0\"\u003eCaution\u003c\/b\u003e Everolimus is heavily processed by the liver. Patients with baseline mild-to-moderate hepatic impairment require careful dose adjustments and intensive monitoring of Everolimus blood trough concentrations. It is generally not recommended for severe liver disease.\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"29\"\u003eLungs\u003c\/h3\u003e\n\u003cp data-path-to-node=\"30\"\u003e\u003cb data-path-to-node=\"30\" data-index-in-node=\"0\"\u003eHigh Caution\u003c\/b\u003e Everolimus can cause non-infectious pneumonitis (inflammation of the lung tissue), which can be severe or life-threatening. Inform your physician immediately if you develop any new or worsening respiratory symptoms, such as a dry cough or shortness of breath.\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"31\"\u003eDriving\u003c\/h3\u003e\n\u003cp data-path-to-node=\"32\"\u003e\u003cb data-path-to-node=\"32\" data-index-in-node=\"0\"\u003eSafe\u003c\/b\u003e Advacan-0.25 Tablets do not typically affect your ability to drive or operate heavy machinery. However, if you experience unexpected fatigue or dizziness, avoid driving until you feel completely alert.\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"33\"\u003ePregnancy\u003c\/h3\u003e\n\u003cp data-path-to-node=\"34\"\u003e\u003cb data-path-to-node=\"34\" data-index-in-node=\"0\"\u003eUnsafe\u003c\/b\u003e This medication can cause serious fetal harm and development issues when given to a pregnant woman. Women of childbearing potential must use highly effective, reliable methods of contraception during treatment and for up to 8 weeks after stopping the medication.\u003c\/p\u003e\n\u003ch2 data-path-to-node=\"35\"\u003eSide Effects of Advacan-0.25 Tablets\u003c\/h2\u003e\n\u003cp data-path-to-node=\"36\"\u003eSide effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them.\u003c\/p\u003e\n\u003cp data-path-to-node=\"37\"\u003eCommon side effects of Advacan-0.25 Tablets are:\u003c\/p\u003e\n\u003cul data-path-to-node=\"38\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"38,0,0\"\u003eMouth ulcers or painful sores in the mouth\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"38,1,0\"\u003eIncreased blood lipid levels (high cholesterol and triglycerides)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"38,2,0\"\u003eSwelling of limbs or face (peripheral edema)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"38,3,0\"\u003eHigh blood pressure (hypertension)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"38,4,0\"\u003eIncreased susceptibility to urinary tract or upper respiratory infections\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"38,5,0\"\u003eNausea, diarrhea, or mild abdominal pain\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-path-to-node=\"39\"\u003eSerious side effects of Advacan-0.25 Tablets are:\u003c\/p\u003e\n\u003cul data-path-to-node=\"40\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"40,0,0\"\u003e\u003cb data-path-to-node=\"40,0,0\" data-index-in-node=\"0\"\u003eNon-infectious Pneumonitis:\u003c\/b\u003e (Persistent dry cough, severe chest tightness, sudden shortness of breath).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"40,1,0\"\u003e\u003cb data-path-to-node=\"40,1,0\" data-index-in-node=\"0\"\u003eSevere Infections:\u003c\/b\u003e (High fever, severe chills, fatigue, sign of localized wound infections due to profound immunosuppression).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"40,2,0\"\u003e\u003cb data-path-to-node=\"40,2,0\" data-index-in-node=\"0\"\u003eAngioedema:\u003c\/b\u003e (Sudden swelling of the face, lips, tongue, or throat causing severe swallowing or breathing difficulties).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"40,3,0\"\u003e\u003cb data-path-to-node=\"40,3,0\" data-index-in-node=\"0\"\u003eNew or Worsening Kidney Issues:\u003c\/b\u003e (Decreased urine output, sudden fluid accumulation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"41\"\u003eWord of Advice\u003c\/h2\u003e\n\u003cp data-path-to-node=\"42\"\u003eNever miss a scheduled laboratory appointment for your Therapeutic Drug Monitoring (TDM) blood tests, as measuring your Everolimus blood concentration levels is the only definitive way your doctor can keep your transplanted organ safe while avoiding systemic drug toxicities. Because this medicine lowers your body's immune defenses, practice excellent personal hygiene, avoid close contact with individuals who have active contagious viral or bacterial illnesses, and wear protective clothing outdoors to minimize the risk of skin damage or infection.\u003c\/p\u003e\n\u003ch2 data-path-to-node=\"43\"\u003eFAQs about Advacan-0.25 Tablets\u003c\/h2\u003e\n\u003cp data-path-to-node=\"44\"\u003e\u003cb data-path-to-node=\"44\" data-index-in-node=\"0\"\u003eQ1. What is Therapeutic Drug Monitoring (TDM) and why is it necessary for Advacan-0.25?\u003c\/b\u003e Everolimus has a narrow therapeutic window, meaning that if the drug level in your blood falls too low, your immune system may reject your new organ, but if it climbs too high, it can cause severe toxicity to your kidneys and liver. Regular blood tests allow your doctor to find the precise sweet spot and adjust your daily tablet counts accordingly.\u003c\/p\u003e\n\u003cp data-path-to-node=\"45\"\u003e\u003cb data-path-to-node=\"45\" data-index-in-node=\"0\"\u003eQ2. Why can't I take my Advacan-0.25 tablet with food on some days and without food on other days?\u003c\/b\u003e Food changes the rate and extent to which Everolimus is absorbed into your bloodstream. If you switch back and forth between taking it with meals and on an empty stomach, your blood levels will fluctuate unpredictably. To keep your levels stable and your transplant safe, choose one method and stick to it strictly.\u003c\/p\u003e\n\u003cp data-path-to-node=\"46\"\u003e\u003cb data-path-to-node=\"46\" data-index-in-node=\"0\"\u003eQ3. Can I drink grapefruit juice while taking Advacan-0.25 Tablets?\u003c\/b\u003e No, you must completely avoid grapefruit, grapefruit juice, and products containing Seville oranges. They contain compounds that inhibit the CYP3A4 enzyme in your gut, which is responsible for breaking down Everolimus. This blockage can cause a sudden, dangerous spike in the medicine's concentration in your blood.\u003c\/p\u003e\n\u003cp data-path-to-node=\"47\"\u003e\u003cb data-path-to-node=\"47\" data-index-in-node=\"0\"\u003eQ4. What should I do if I develop painful mouth ulcers while taking this medicine?\u003c\/b\u003e Mouth sores (stomatitis) are a very common side effect of mTOR inhibitors like Advacan. Avoid eating spicy, acidic, or very crunchy foods that can irritate your mouth. Your transplant team can prescribe special, alcohol-free therapeutic mouthwashes or topical gels to relieve pain and help the sores heal.\u003c\/p\u003e\n\u003cp data-path-to-node=\"48\"\u003e\u003cb data-path-to-node=\"48\" data-index-in-node=\"0\"\u003eQ5. How long do I need to keep taking Advacan-0.25 Tablets after my transplant surgery?\u003c\/b\u003e Immunosuppressive therapy following an organ transplant is typically a lifelong requirement to prevent graft rejection. Never stop taking your medication, skip a dose, or alter your schedule without explicit orders from your transplant specialist.\u003c\/p\u003e\n\u003ch2 data-path-to-node=\"49\"\u003eFact Box of Advacan-0.25 Tablets\u003c\/h2\u003e\n\u003cul data-path-to-node=\"50\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"50,0,0\"\u003e\u003cb data-path-to-node=\"50,0,0\" data-index-in-node=\"0\"\u003eMolecule name:\u003c\/b\u003e Everolimus (0.25mg)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"50,1,0\"\u003e\u003cb data-path-to-node=\"50,1,0\" data-index-in-node=\"0\"\u003eTherapeutic class:\u003c\/b\u003e Immunosuppressants\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"50,2,0\"\u003e\u003cb data-path-to-node=\"50,2,0\" data-index-in-node=\"0\"\u003ePharmacological class:\u003c\/b\u003e mTOR Inhibitors (Proliferation Signal Inhibitors)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"50,3,0\"\u003e\u003cb data-path-to-node=\"50,3,0\" data-index-in-node=\"0\"\u003eIndications:\u003c\/b\u003e 1. Prophylaxis of organ rejection in adult patients receiving an allogeneic kidney transplant. 2. Prophylaxis of organ rejection in adult patients receiving an allogeneic liver transplant.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"51\"\u003eReferences\u003c\/h2\u003e\n\u003col start=\"1\" data-path-to-node=\"52\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"52,0,0\"\u003eTedesco-Silva H, et al. Everolimus early introduction and cyclosporine minimization in kidney transplantation. \u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003ca rel=\"noopener\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26107153\/\" class=\"ng-star-inserted\" data-hveid=\"0\" data-ved=\"0CAAQ_4QMahgKEwjixcTjm8KUAxUAAAAAHQAAAAAQxgU\" target=\"_blank\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/26107153\/\u003c\/a\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"52,1,0\"\u003eEisen HJ, et al. Everolimus for the prevention of allograft rejection in cardiac transplant recipients. \u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003ca rel=\"noopener\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14602879\/\" class=\"ng-star-inserted\" data-hveid=\"0\" data-ved=\"0CAAQ_4QMahgKEwjixcTjm8KUAxUAAAAAHQAAAAAQxwU\" target=\"_blank\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/14602879\/\u003c\/a\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"52,2,0\"\u003eOrgan Transplantation Medical Evaluation Group. National Guidelines on Immunosuppressive Therapy Management. [Updated 2026]. Available from: \u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003ca rel=\"noopener\" href=\"https:\/\/www.google.com\/search?q=https:\/\/clinicalinfo.org\/\" class=\"ng-star-inserted\" data-hveid=\"0\" data-ved=\"0CAAQ_4QMahgKEwjixcTjm8KUAxUAAAAAHQAAAAAQyAU\" target=\"_blank\"\u003ehttps:\/\/clinicalinfo.org\/\u003c\/a\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"52,3,0\"\u003eFood and Drug Administration (FDA). Zortress (Everolimus) Oral Tablets Prescribing Information \u0026amp; Blood Trough Tracking Protocols. \u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003ca rel=\"noopener\" href=\"https:\/\/www.google.com\/search?q=https:\/\/www.accessdata.fda.gov\/\" class=\"ng-star-inserted\" data-hveid=\"0\" data-ved=\"0CAAQ_4QMahgKEwjixcTjm8KUAxUAAAAAHQAAAAAQyQU\" target=\"_blank\"\u003ehttps:\/\/www.accessdata.fda.gov\/\u003c\/a\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c!----\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2 data-path-to-node=\"53\"\u003eDisclaimer\u003c\/h2\u003e\n\u003cp data-path-to-node=\"54\" id=\"p-rc_b95995a0b4755985-40\"\u003eMedipoint India’s primary intention is to e\u003cspan class=\"citation-59 citation-end-59\"\u003ensure that its consumers get accurate, trustworthy, and expert-reviewed information. The contents of this website are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss\u003csup class=\"superscript\" data-turn-source-index=\"1\"\u003e\u003c!----\u003e\u003c\/sup\u003e\u003c\/span\u003e all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Medipoint India. Our mission is to support, not replace, the doctor-patient relationship.\u003c\/p\u003e","brand":"Medipoint India","offers":[{"title":"Default Title","offer_id":47891362611418,"sku":null,"price":483.0,"currency_code":"INR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0821\/2332\/5658\/files\/advacan-0-25mg-tablet.jpg?v=1779088288","url":"https:\/\/www.medipointindia.com\/products\/advacan-0-25-tablets","provider":"Medipoint India","version":"1.0","type":"link"}